Look up one drug

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Citalopram · DIN 02387956 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-11-30 Health Canada: Marketed since 2024-02-27 · brand CITALOPRAM · ATC N06AB04 CITALOPRAM · form Tablet · route Oral · ingredients CITALOPRAM (CITALOPRAM HYDROBROMIDE) 20 MG · company Sivem pharmaceuticals ulc · schedule Prescription

DIN 02387956: Citalopram Raw flags: sec3=Y Item: 281604096; group id 454; item number 1133; lccId None; manufacturer id SIV Source form: Tab; strength: 20mg Recorded listing: General benefit Source prices (unrounded): $0.1332; ministry $0.1332 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02387956 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87352

Interchangeable products

Accel Citalopram Tablets · DIN 02355256 · $0.1332 Apo-Citalopram · DIN 02246056 · $0.1332 Auro-Citalopram · DIN 02275562 · $0.1332 CCP-Citalopram · DIN 02459914 · $0.1332 Celexa · DIN 02239607 · $0.1332 Citalopram · DIN 02353660 · $0.1332 Citalopram · DIN 02430541 · $0.1332 Co Citalopram · DIN 02248050 · $0.1332 Jamp-Citalopram · DIN 02313405 · $0.1332 M-Citalopram · DIN 02467836 · $0.1332 Mar-Citalopram · DIN 02371898 · $0.1332 Mint-Citalopram · DIN 02429705 · $0.1332 NRA-Citalopram · DIN 02477645 · $0.1332 Natco-Citalopram · DIN 02443880 · $0.1332 PMS-Citalopram · DIN 02248010 · $0.1332 Ran-Citalo · DIN 02285622 · $0.1332 Riva-Citalopram · DIN 02303264 · $0.1332 Sandoz Citalopram · DIN 02248170 · $0.1332 Septa-Citalopram · DIN 02355272 · $0.1332 Teva-Citalopram · DIN 02293218 · $0.1332

Shortage status: resolved shortage (ended 2021-10-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02387956

Shortage record checked 2026-09-13T08:10:21.292534+00:00